Syntax Bio Announces Collaboration with Mayo Clinic to Advance Pancreatic Cell Therapy for Type 1 Diabetes
Collaboration seeks to accelerate translation and development of stem cell-derived pancreatic cells
Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes.
Under the collaboration, the teams seek to define and develop an allogeneic pancreatic beta cell therapy for insulin-dependent diabetes based on patient needs. Syntax Bio plans to use its proprietary CellgorithmTM platform to guide induced pluripotent stem cells into beta cells. Mayo Clinic will provide expertise in pancreatic biology and functional testing in preclinical diabetes models to support regulatory-enabling studies and early clinical development.
“The collaboration reflects our belief that regenerative medicine must start with precise control over cell identity and function,” said John Craighead, chief executive officer of Syntax Bio. “By combining our Cellgorithm platform with Mayo Clinic’s translational and clinical expertise, we aim to accelerate the development of a next-generation cell therapy with transformative real-world benefits for patients with type 1 diabetes.”
